A secret shopper investigation of 49 websites prescribing GLP-1 weight loss drugs confirmed experts' concerns about inadequate clinical oversight and fast, easy prescriptions with minimal medical evaluation.
Mayo Clinic study finds metabolic and bariatric surgery provides significantly greater long-term cardiovascular risk reduction compared to GLP-1 medications in people with obesity, despite both treatments improving heart health.
Researchers who developed GLP-1 obesity medications are now advancing a provocative hypothesis that targeting the GLP-1 hormone may not be necessary for effective weight loss, potentially reshaping the approach to obesity treatment.
